Karolien Adriaens obtained her Master’s degree in Clinical Psychology in 2014. During her Masters, she conducted one of the first RCT’s concerning electronic cigarettes. Currently, she is pursuing a Ph.D. in Psychology at the Centre for the Psychology of Learning and Experimental Psychopathology at the KU Leuven. Her main research interests are tobacco harm reduction, electronic cigarettes, and newly developed harm reduction tools, such as heat-not-burn cigarettes. Karolien is investigating the effect of electronic cigarettes as a harm reduction tool in different groups of current smokers: first time e-cigarette users, dual users and smokers who visit a tobacco counselor to quit smoking.
Peter Beckett is Managing Director of Beckett Associates, a specialist management consultancy that helps vaping companies survive and grow while navigating political and regulatory risk around the world. Before starting his firm, he spent nearly three years as Head of Public Policy for ECITA, where he was responsible for industry-level political advocacy during the procedure that led to the passage of the Tobacco Products Directive. He has also been instrumental in its implementation, is an expert in compliance with its requirements and was at the centre of negotiations that led to the formation of CEN TC 437 on electronic cigarettes and e-liquids. He has worked and consulted for a range of leading vapour companies in the EU, US and China; and for the US Vapor Technology Association on their campaign against unworkable FDA regulation of the vaping sector.
Veronica is in the final year of her PhD. She has worked in the nicotine and tobacco research area for over five years and her studies focus on smoking and social disadvantage. Her work is embedded with high consumer engagement and aims to improve delivery of new and enhanced evidence-based cessation strategies for disadvantaged smokers.
Thomas Brandon, Ph.D. is Chair of the Department of Health Outcomes and Behavior at the H. Lee Moffitt Cancer Center and Research Institute, in Tampa, Florida, where he also directs the Tobacco Research and Intervention Program. He has over 30 years of experience studying factors that maintain tobacco dependence and developing novel, theory-based tobacco-cessation and relapse-prevention interventions, particularly self-help approaches. He co-authored Annual Review articles on smoking motivation and relapse/relapse prevention and is the former journal editor of Psychology of Addictive Behaviors. Recently, Dr. Brandon has expanded his research to study the addiction mechanisms and potential clinical utility of e-cigarettes.
Cynthia Cabrera is a seasoned expert in the vapor space,involved in the vapor industry since 2011. As Founder and president of The Cating Group, Cynthia and her team provide business-consulting services including compliance, manufacturing operations, restructuring, government affairs, and business development including new product rollout and strategic partnerships. She is a frequent speaker on trends, product evolvement, distribution channels, and regulatory and legislative issues. Cynthia has presented for The Tobacco Merchants Association (TMA), The Global Tobacco Nicotine Forum (GTNF), the Global Forum on Nicotine (GFN), The Food & Drug Law Institute (FDLI,), The Responsible Retailers Forum (RRF), ECIG USA, the Morven Dialogues and a wide variety of vapor shows and exhibits.
Oscar M. Camacho is the scientific data and statistics manager at British American Tobacco (BAT). A trained Statistician and Bioinformatician with a Masters in biometrics and a Masters in applied bioinformatics with a background in teaching and the financial sector, he joined BAT’s research and development function in 2010 as a technical specialist in statistics. In his current role, he leads a team providing R&D with support in statistics, data management, bioinformatics, and mathematical modelling. A key area of his work is contributing to the reduced-risk substantiation work streams ensuring appropriate study design, sound data analysis techniques, and reporting are applied throughout studies’ life cycles. Working with experts in the field of system dynamics, he has developed and published the findings from a population model assessing the potential effects on mortality from launching e-cigarettes in the U.K. After model validation activities with snus data in Sweden and cross-validation with other models, he has been working on further model applications, such as a model implementation, to study the potential effects from launching new nicotine products in the U.S. market.
Dr Brian Carter is the Director of Scientific Communications for the Consumer Advocates for Smoke-free Alternatives (CASAA). Trained as a clinical psychologist, Dr. Carter’s field of study is addictive behavior, with a focus on the pharmacological, psychological, and behavioral foundations of tobacco and nicotine use, dependence, and motivation. As a faculty member in the Department of Behavioral Science at the University of Texas M.D. Anderson Cancer Center, he conducted multiple National Cancer Institute funded laboratory studies on nicotine use in cigarette smokers. He has widely published his findings in academic journals and has presented at numerous national and international scientific conferences.
Martin Cawley joined the Big Lottery Fund in September 2016 as Director for Scotland following a successful period as chief executive of Turning Point Scotland. Martin has worked in practitioner, management and leadership positions in both the statutory and voluntary sectors for over 34 years. Martin has extensive experience of developing and managing person centered services designed to support people achieve full and active citizenship. Over the years he has also been a board member of a number of smaller organisations including national umbrella agencies and social enterprises aimed at improving practice and approach and influencing social policy.
Martin is a huge fan of all kinds of sports and enjoys participating in one or two every now and again. He also loves travelling and spending time with his family.
Gregory Conley is the president of the American Vaping Association (AVA), a nonprofit organization that champions regulatory policies toward vapor products designed to maximize the effectiveness of vaping for quitting smoking. He is one of the most prominent defenders of vaping in the United States and has appeared on CNN, Fox News, and MSNBC. In addition to his work with the AVA, Mr. Conley is an attorney and a consultant on vaping legislative and regulatory issues. He began working on vaping issues in 2010 after quitting smoking with a vapor product while in law school. He served as the pro bono legislative director for the Consumer Advocates for Smoke-Free Alternatives Association from 2011 to 2014.
Dr Sharon Cox has over ten years’ experience working in the drug and alcohol field, including working at front-line services with some of the UK’s most deprived communities. She has a special interest in harm reduction and the use of translational methodologies in vulnerable and marginalised groups. She currently works as a Research Fellow at London South Bank University’s Centre for Addictive Behaviours Research. Her current research is focused on e-cigarette puffing patterns associated with high and low nicotine e-liquid strength, smoking and alcohol consumption within disadvantaged groups and the impact of health warning labels on reduced risk products.
Martin Cullip is a transport company director who uses e-cigarettes and other reduced risk nicotine products and has seen a positive shift in recent years of his staff members quitting or reducing smoking by vaping instead. He is a passionate consumer advocate of all forms of tobacco harm reduction and is an Associate of the New Nicotine Alliance as well as an adviser to the Freedom Association’s Freedom to Vape campaign. He has a keen interest in the rapidly-evolving nicotine market, in particular the politics surrounding it, and has taken part in consumer, industry and political events on the subject from Bournemouth to Brussels and beyond. Martin has also written and blogged for a decade on a diverse range of lifestyle and free market issues for a number of media outlets such as Spiked, International Business Times, The Free Society, advocacy websites and others.
Konstantinos E. Farsalinos, M.D., is a research fellow at the Onassis Cardiac Surgery Center in Athens-Greece, at the Department of Pharmacy, University of Patras-Greece and at the National School of Public Health-Greece. He has been conducting laboratory and clinical research on e-cigarettes as a principal investigator since 2011. Examples of his work include the first study on the cytotoxic effects of e-cigarette vapor on cultured cells and the immediate effects of e-cigarette use on cardiac function and coronary circulation. He ran a worldwide online survey of almost 20,000 vapers (users of e-cigarettes) identifying patterns of use and experience with e-cigarettes among consumers, published in 2014. He has analyzed patterns of e-cigarette use based on large European and US population surveys (Eurobarometer, National Youth Tobacco Survey). Additionally, he is performing research work on heated tobacco products. His research findings have been presented in major international scientific congresses and his studies were used in preparing the regulatory framework on e-cigarettes by the European Union. As of early 2018, he has published more than 60 studies and articles in international peer-reviewed scientific journals about smoking, tobacco harm reduction, and e-cigarettes. He was the handling editor and author in a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017.
Amy Fairchild is a historian who works at the intersection of ethics and policy. Her work harm reduction, privacy and surveillance, and immigration and border control is fundamentally concerned with the politics of public health and the tensions between ethics and evidence. In addition to her publications in leading journals, Fairchild is the author of two books Science at the Borders: Disease and the Making of the Modern Industrial Labor Force and Searching Eyes: Privacy and Disease Surveillance in America. Her current work includes a cross-national project on harm reduction and ethics and politics of e-cigarettes.
Daniel is an Associate Professor in Psychology, with a particular focus on habitual behaviours. He has authored over 40 publications, including journal articles, book chapters, a popular press psychology book and a concise overview of social psychology aimed at students. Daniel has received funding from Cancer Research UK, the Economic Social Research Council, British Academy, Alcohol Research UK, the European Regional Development Fund and both commercial and third sector partners. He is currently leading a clinical RCT comparing two stop smoking treatments (ISRCTN23584477). He has also published widely in the field of psychophysiology, and is an Associate Editor of the Journal of Applied Social Psychology.
Joe Gitchell provides strategic counsel to clients across a wide range of health policy, regulatory, and marketing and communications challenges. With a focus on client service, Joe leads efforts supporting regulatory approvals, conducting public policy analysis, developing communications approaches, devising, refining and defending claims, and providing input on strategic market opportunities and directions.
He has counseled clients navigating health policy and communications challenges in the US, Europe, Latin America, Asia and the Middle East.
Professor Marewa Glover has worked on reducing smoking-related harm for over 25 years. She has worked as a policy analyst, a co-ordinator of a national tobacco control programme, cessation trainer and, for over 17 years, as a researcher. She has chaired numerous committees and organisations including End Smoking NZ, an independent NGO that lobbied for a harm reduction approach even before electronic cigarettes were introduced. Marewa has over 100 publications reflecting her leadership and support of numerous studies. Her primary focus has been reducing smoking during pregnancy and reducing smoking among Māori, the indigenous people of New Zealand. She has also been a co-investigator on a number of innovative cessation projects and a longitudinal online survey of New Zealand vapers. Dr Glover is the most prominent public commentator on vaping in NZ. She is regularly called by the media and has appeared on NZ’s 60 Minutes in addition to participating in live online and conference debates about vaping. Despite an initial ban on the import and sale of nicotine for vaping imposed by the Ministry of Health, vaping has become established as a common and successful way to reduce or stop smoking in NZ. Marewa, along with a small number of other researchers who early on foresaw the potential of ecigs, have helped make this happen.
Robyn Gougelet works at PinneyAssociates and advises on public health legislative and regulatory policy strategy for tobacco harm reduction efforts and execute on targeted efforts. PinneyAssociates provides consulting services on smoking cessation and tobacco harm minimization (including nicotine replacement therapy and electronic vapor products) to Niconovum USA, Inc., R.J. Reynolds Vapor Company, and RAI Services Company, all subsidiaries of Reynolds American Inc. RAI was acquired by British American Tobacco (BAT) in July 2017.
Before joining PinneyAssociates as an Associate in June 2015, Robyn worked for three years at Trust for America’s Health (TFAH), a non-profit, non-partisan organization in Washington, D.C. dedicated to saving lives by protecting the health of every community and working to make disease prevention a national priority. In that role, Robyn helped to inform Members of Congress and their staff about state-specific prevention and public health provisions and programs created by the Affordable Care Act. As part of her work at TFAH, Robyn advocated for public health programs during the appropriations process. Before joining TFAH, Robyn worked as an intern in the office of Senator Jeanne Shaheen. Robyn graduated magna cum laude from the University of Maryland with an honors degree in History and was elected to Phi Beta Kappa. As an undergraduate, she also studied history and politics as a visiting student at Lady Margaret Hall at the University of Oxford.
Richard Holliday is a Speciality Registrar (StR) in Restorative Dentistry and NIHR Doctoral Research Fellow at Newcastle University. Richard’s research interests are focused on periodontal diseases, particularly risk factors, and he is currently completing his PhD on ‘e-cigarettes as a smoking cessation or harm reduction tool for patients with periodontitis’. The main body of this work is a feasibility randomised controlled trial of 80 smokers with periodontitis. Additional projects include surveys of tobacco education in UK dental schools, surveys of practitioner opinions and in vitro analysis.
Amelia Howard studies the emergence of the independent vaping market, and the response of industries, regulators, and social movements this market disrupts.
Martin Jarvis is Emeritus Professor of Health Psychology at the Department of Epidemiology and Public Health, University College London. Over the past 35 years he has researched and published widely on tobacco smoking, with special interests in the role of nicotine, social and family influences on smoking, smoking cessation methods and passive smoking. He is a trustee of ASH, and was Deputy Chair of the UK government’s Scientific Committee on Tobacco and Health and Specialist Adviser to the House of Commons Health Committee’s inquiries into tobacco and health and into smoking in public places. He was awarded an OBE in 2002 and was given the John Slade award of the Society for Research on Nicotine and Tobacco in 2008.
Dr Bethea (Annie) Kleykamp is a Scientist at the health-care consulting firm, PinneyAssociates. She earned her PhD at Virginia Commonwealth University and completed postdoctoral training at the Johns Hopkins University School of Medicine and the Intramural Program of the National Institute on Drug Abuse. Her research focused on the cognitive effects of a variety of psychoactive drugs (e.g., nicotine, alcohol, methadone). Prior to joining PinneyAssociates in 2014, she worked at the health technology assessment company, Hayes, Inc., where she wrote systematic reviews that informed healthcare decisions for government, health insurance, and healthcare provider clients. Currently her responsibilities at PinneyAssociates include conducting literature reviews, interpreting and synthesizing data, and applying her writing skills across a variety of content areas (e.g., tobacco harm minimization, prescription to over-the-counter switch, risk management).
Doctor, speaker, author, media presenter and health industry consultant, Dr Joe Kosterich wants you to be healthy and get the most out of life. Joe writes for numerous medical and mainstream publications and is also a regular on radio and television. He is often called to give opinions in medico legal cases and he is also an adjunct professor (teaching) at UWA. He is on the editorial advisory panel of Medical Forum Magazine and Reed Medical Conferences.Dr Joe maintains a website and blog with health information and commentary.
He self-published two books: Dr Joe’s DIY Health and 60 Minutes To Better Health.Previously he held senior positions in the Australian Medical Association and sat on numerous industry and government boards. He has extensive corporate experience in the setting up and management of medical centres and in helping businesses maintain a healthy workforce. Through all this he continues to see patients as a GP each week.His interest in E-Cigarettes has come from listening to the experience of patients. This is both those struggling to quit smoking and those whose success has come from vaping.
Trained neuroscientist in Paris (PhD in 1988) who spent 2 years as a post-doctoral fellow in Clinical Pharmacology & Experimental Therapeutics at the University of California. After 6 years of research in La Salpêtrière Hospital (Paris), and teaching at Paris V and Paris VII Universities, he became a freelance consultant for the pharmaceutical industry and the public sector (training smoking cessation specialists, and writing monthly scientific digests for them). He is a Charter Member of SRNT and was part of the core group who founded SRNT Europe. He participated in the Steering Committee of the WHO Europe Partnership Project to reduce Tobacco Dependence (1991-2001), and was also on the European Commission’s Scientific Committee on Emerging and Newly Identified Health Risks (SCHENIR) expert group on smokeless tobacco (2006-2008). He is also Honorary Lecturer, UK Centre for Tobacco Control Studies, University of Nottingham, England, and manager of www.treatobacco.net the SRNT & SSA website dedicated to tobacco dependence treatment.
David Levy has a PhD in Economics from UCLA and is currently a Professor of Oncology at Georgetown University. He has published over 250 articles, including in the American Economic Review, BMJ, AJPH, JAMA, Lancet, Tobacco Control, and PLOS Medicine. He has been principal investigator of grants from the CDC, WHO, the National Cancer Institute, and Bloomberg/Gates Foundation. Dr. Levy is currently overseeing the design and development of the SimSmoke tobacco policy simulation model, which he has developed models for over 40 countries covering 85% of the world population. He is now developing models of smokeless tobacco and e-cigarette use.
Dr Roberto A Sussman is the founder and Director of Pro-Vapeo Mexico, an association representing Mexican consumers of non-combustible nicotine products and member of INNCO. Dr Sussman is actively advocating for an appropriate regulation of Tobacco Harm Reduction products in Mexico. As a full time senior researcher in physics at the National University of Mexico (UNAM), he directs and supervises the effort to spread scientific information on these products, as well as advising consumers on how to counter the misinformation and prejudice about them that is rampant throughout Latin America
Karl Erik Lund is Senior Researcher at the Norwegian Institute of Public Health. He has been involved in tobacco control work since the mid 1980s, working at the Norwegian Council on Tobacco or Health (Deputy Leader), the Norwegian Cancer Society (Director for Department of Cancer Prevention) and Norwegian Institute for Alcohol and Drug Research (Research Director). Dr. Lund received the Norwegian Medical Association’s Award in preventive medicine in 2000. He is well published within tobacco research, has been a lecturer on tobacco topics in several countries worldwide, and has been a member of several expert committees on tobacco control including WHO’s International Agency for Cancer Research (IARC). He has been an expert witness in several court cases against the tobacco industry in Norway. Dr. Lund has been Associate Editor in the scientific journal Nicotine & Tobacco Research since 2011 and Senior Associate Editor of Tobacco Regulatory Science since 2015.
Dr Kgosi Letlape, is currently the President of the HPCSA and Chairperson of the Medical and Dental Board. Dr Letlape obtained his MBChB degree in medicine from the University of KwaZulu Natal in 1981.
In 1988, he completed his FSC (OPHTH) degree in Ophthalmology at the College of Ophthalmology Medicine South Africa. In the same year he obtained his FRCS (OPHTH) degree in Ophthalmology at the University at Edinburgh. PROFESSIONAL ACTIVITIES: Board Member: South African Medical & Dental Practitioners, Johannesburg: 1989 – 1995; Vice Chairperson: South African Medical & Dental Practitioners, Johannesburg: 1990 – 1994; Chairperson: South African Medical & Dental Practitioners: 1994 – 1995; Chief Executive Officer: Phelo-Ntle: 1996 – 1997; Chairperson: National Council of the South African Medical Association: 2001 – 2009; President: World Medical Association (WMA): 2005 – 2006; Co- chair of the Prevention Task Team of (SANAC): 2007 – 2009; President of Africa Medical Association: 2006; Member of the Global Hygiene Council; President HPCSA October 2015
Colin Mendelsohn is an Associate Professor in the School of Public Health and Community Medicine at the University of New South Wales, Sydney, Australia. He is a medical practitioner and tobacco treatment specialist working in private practice and is Chairman of the Australian Tobacco Harm Reduction Association. He is actively involved in raising awareness of the public health benefits of tobacco harm reduction and advocating for the legalisation of vaping in Australia. His activities in the smoking cessation field include teaching medical students and health professionals, writing, research, public education and consulting to the pharmaceutical industry. Colin is a member of the committee that develops the Australian national smoking cessation guidelines and is past Vice President of the Australian Association of Smoking Cessation Professionals.
Dr. James Murphy holds a PhD in polymer chemistry and joined us in 2005 after postdoctoral research at the Nara Institute of Science & Technology in Japan developing novel polymer-based drug delivery systems. He has held a variety of roles in R&D, including leading the development and assessment of a Reduced Toxicant Prototype cigarette, as well as development and commercialisation of Vype e-cigarettes. He now heads up our Reduced Risk Substantiation unit, overseeing all of our pre-clinical and clinical research programs. His group is working on research methodologies to substantiate the reduced-risk potential of next-generation products.
Paul Newhouse, M.D. holds the Jim Turner Chair in Cognitive Disorders at Vanderbilt University School of Medicine and is Professor of Psychiatry, Pharmacology, and Medicine. He is Director of the Vanderbilt Center for Cognitive Medicine (VCCM) in the Department of Psychiatry and Behavioral Sciences at Vanderbilt University Medical Center. The VCCM focuses on research studies of the cognitive basis of neuropsychiatric disease. Dr Newhouse established the Division of Geriatric Psychiatry Division and the Geriatric Psychiatry Fellowship at Vanderbilt and was the inaugural director of both. He is also a physician-scientist at the Veterans Affairs Tennessee Valley Health Systems Geriatric Research, Education, and Clinical Center (GRECC). He is an Army veteran and among other posts, served in the 3rd Infantry Division, directed a research laboratory for the Walter Reed Army Institute of Research, and served in Operation Desert Storm.
Current studies in his laboratory include leading a national study of the effects of nicotinic treatment for mild cognitive impairment, the treatment of post-cancer chemotherapy cognitive impairment, the development of novel muscarinic cholinergic agents for Alzheimer’s disease, cholinergic mechanisms in HIV and aging, studying new agents for the treatment of Alzheimer’s disease and cognitive impairment in older adults with Down syndrome, and the development of socially-assistive robots for dementia care. His research has been continuously funded by NIH since 1989 and he is funded currently by the National Institute on Aging, the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation, and other private companies and foundations.
Dr Notley is a Senior Lecturer in Mental Health at the Norwich Medical School, University of East Anglia, and a Research Fellow of the UK Society for the Study of Addiction. She is a social scientist with extensive experience in Addiction research. Her current programme of research is focused on tobacco smoking relapse prevention, particularly working with vulnerable groups. Dr Notley’s research interests in alternative nicotine delivery devices primarily explores social and culturally pertinent aspects of vaping. Her work emphasises the public health potential of vaping for smoking relapse prevention, taking a ‘real world’ perspective to highlight the importance of user focused perspectives on switching from traditional smoking to vaping. Dr Notley, as Chair of the Scientific Committee, has an independent role in overseeing the scientific content of the conference. The role includes assessment of the Early Career Travel Awards which are funded from the GFN conference budget. Dr Notley receives no funding for this voluntary role.
Dr Sudhanshu Patwardhan is a medical doctor and an MBA with two decades of international experience in biomedical research and regulatory strategy in the pharmaceutical and tobacco industries. He has been with the British American Tobacco Group for the past thirteen years, focusing on nicotine policy, product science and KOL engagement. Sud passionately believes in the role of educating health care professionals in achieving tobacco harm reduction globally. He keenly tweets as @DocTHRNic, primarily on tobacco control challenges in LMIC. Sud lives in Hampshire, England, with his wife and two children. He loves Indian music and is very active as a Director of the charity Art Asia, UK.
Helen Redmond, is an expert in substance use with over a decade of experience working with drug users and people with mental health problems in medical and mental health settings and in community supportive housing. Her current focus is on helping vulnerable and stigmatized populations transition to e-cigarettes. She is an independent journalist and writes about vaping, mental health and drug policy. Helen is a filmmaker and made a short documentary about people with serious mental health problems and smoking. She provides tobacco harm reduction trainings via her consulting firm, Nicotine Harm Reduction Consultants. She is adjunct faculty at New York University - Silver School of Social Work.
Louise Ross was the leader of the Leicester City Stop Smoking Service. Louise finished a very happy and long working life in learning disabilities to work in tobacco control and smoking cessation, and has been delighted to discover a second career that has been even more satisfying than the first. Initially sceptical about ecigs, she has become a vocal advocate for their use as a harm reduction method, principally because she has listened to people who have used them to stop smoking, and has been utterly convinced by their sincerity. Louise is an associate of the New Nicotine Alliance UK, a charity committed to improving public health through a greater understanding of risk-reduced nicotine products. Louise now does freelance and unpaid advocacy work about stopping smoking and vaping.
Ed Stephens is Senior Research Fellow in the School of Earth & Environmental Sciences at the University of St Andrews (Scotland, UK). He has held visiting positions in France (Toulouse) and Australia (ANU). His training is in geochemistry with a current interest in modelling environmental pathways of toxicants and carcinogens. This began with modelling the controls on valence speciation of metals in tobacco and more recently has focused on chemical aspects of emissions in e-cigarettes and other forms of nicotine delivery. His research has been supported by UK research councils, NIH, EU and medical charities.
Rajesh N. Sharan, Ph. D., is a Professor at Department of Biochemistry and Director of Design Innovation Center at North-Eastern Hill University, Shillong (India). Rajesh is a Molecular Biologist and Biochemist by training with over 3 decades of research experience in the field of betel (Areca) nut & chemical induced carcinogenesis, and molecular mechanisms of radiation induced damage to DNA & its repair with expertise in biomarker discovery for cancer and radiation damage assessment for their clinical applications. Rajesh is a former President of Indian Society for Radiation Biology and currently a member of CRP of IAEA (Vienna). He has over 105 research publications & books, and few patents to his credit. Rajesh serves as an Associate Editor of the Journal of Radiation Research. Since last year, Rajesh has developed keen interest in the field of tobacco harm reduction in India and initiated research in this area.
Mohamadi Sarkar, M.Pharm., Ph.D., FCCP, serves as Senior Principal Research Scientist for Altria Client Services in Richmond, Va. He has held this position since August 2002. In his current role Dr. Sarkar provides strategic direction for developing the scientific evidence on reduced risk products made by Altria Group’s tobacco companies. He has authored more than 100 scientific peer-reviewed publications and presentations at scientific meetings. Dr. Sarkar also has participated in several invited seminar presentations and authored a variety of scientific book chapters related to his areas of expertise. Before joining the Altria family of companies, Dr. Sarkar served as Associate Professor, Clinical Pharmacology for the Medical College of Virginia (MCV) at Virginia Commonwealth University in Richmond between1998-2002. He is currently affiliate Professor of Pharmacology and continues to teach Clinical Pharmacology. Between 1990 and 1998, Dr. Sarkar worked at West Virginia University in Morgantown, W.Va., where he held a variety of positions including: Associate Professor, Clinical Pharmacology; Associate Professor, Genetics, and Developmental Biology; and Associate Professor, Tobacco Research Center, WVU Cancer Center. Dr. Sarkar received his bachelor’s in Pharmacy from the College of Pharmacy, University of Bombay in 1981, a master’s in Pharmaceutical Technology, University of Bombay in 1985 and a Ph.D. in Clinical Pharmacology, Medical College of Virginia at VCU in 1990. He is also a Fellow of the College of Clinical Pharmacology.
Paweł Juliusz Skutecki, Politician and Polish journalist, member of the Sejm of the 8th term. Graduated in Polish Philology at the Academy of Bydgoszcz and he was studying philosophy at the University of Warsaw as well. During the parliamentary elections of 2015, he was a candidate for the Sejm in the Bydgoszcz's constituency and he got first place over the voters' electoral committee list organized by Mr. Paweł Kukiz. He is a member of the Health Committee in Polish Parliament.
Professor Gerry Stimson is a public health social scientist, with over 40 years’ experience of research and advocacy. He was one of the founders of drugs harm reduction in the 1980s and helped develop and evaluate harm reduction in the UK as a response to HIV/AIDS. He has advised the UK Government, World Health Organization, UNAIDS, UNODC, World Bank and numerous governments on issues relating to drugs, HIV infection and AIDS, and alcohol. He is an advocate for tobacco harm reduction as a key public health strategy for reducing smoking related harms. He was a member of the UK National Institute for Health and Clinical Excellence guidelines group on tobacco harm reduction, and is a member of the British Standards Institute working group on e-cigarette standards. He helps organise the Global Forum on Nicotine conference. He has published over 220 scientific publications and several books. He is Honorary Professor at the London School of Hygiene and Tropical Medicine, Emeritus Professor at Imperial College London, and recent past Editor of the International Journal of Drug Policy. He was Executive Director of the International Harm Reduction Association from 2004 to 2010.
Nancy Sutthoff is the Co-founder and Co-Director of Aotearoa Vapers Community Advocacy (AVCA) in New Zealand. AVCA was officially formed in April 2016 to address the rights of vapers in New Zealand in response to the lack of legislation/regulation/guidance from the national level of government, and local councils misapplication of SmokeFree laws towards Vaping. Nancy has a diverse background with degrees in Police Sciences (A.A.S) and Sociology (B.A) she has always, in one way or another, been involved in investigative and advocacy roles, from business analysis of corporate IT systems to research administration at SUNY Stony Brook (New York, USA) to local government relations for the West Boca Community Council (Florida, USA) to youth health and education advocacy (New Zealand). Nancy’s motivation has been, and always will be, to educate people on their options, to support them in their choices and to honour the memory of her mother (who died young of smoking related disease) by standing up for those whose voices are usually not heard, and fighting with them for their rights to self determination, be it their health or otherwise.
David Sweanor is chair of the advisory board of the Centre for Health Law, Policy & Ethics, and an adjunct professor, Faculty of Law, University of Ottawa. He has been actively involved in tobacco and health policy issues since the beginning of the 1980s and played a leading role in setting many global precedents. He has worked with numerous groups globally, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization. The current focus of his tobacco related work is on risk reduction strategies. He is also actively engaged on a broad range of other issues and was awarded Ottawa’s Outstanding Individual Philanthropist award in 2016.
Frances Thirlway is a Research Fellow at the University of York working on health, class and culture; her interest in e-cigarettes is mainly in relation to their potential to address health inequalities by increasing smoking cessation in populations with high smoking prevalence. Frances is Principal Investigator on a project funded by Cancer Research UK entitled ‘Electronic cigarettes, health inequalities and smoking cessation: a community study of take-up and market evolution in two high smoking prevalence areas of the North of England’. The project runs from April 2017 to March 2019 and involves fieldwork in County Durham and North Manchester with smokers, quitters and electronic cigarette users as well as e-cigarette vendors. Frances is bilingual in French and hopes to extend her research to the ex-mining areas of Northern France. She attended Vapexpo 2017 in Paris and has carried out pilot research with e-cigarette users and vendors in the towns of Douai and Valenciennes.
Prof. Aleksei Trofimov received M.Sc. (1988) and Ph.D. (1991) degrees in physics and mathematics from the Moscow Institute of Physics and Technology (State University) and D.Sc. ("Habilitation") degree in chemistry (2005) from the Russian Academy of Sciences. During his academic career, he held positions at the Institutes of Chemical/Biochemical Physics, Russian Academy of Sciences (Moscow, Russia), as Senior Scientist and Leading Scientist, and at the University of Würzburg (Germany), as the postdoctoral fellow and the Senior Research Associate with Prof. Waldemar Adam. Currently, he holds position of Deputy Director of the Emanuel Institute of Biochemical Physics, Russian Academy of Sciences.
Carrie Wade is a senior fellow and the harm reduction policy director for the R Street Institute. She joined R Street in 2017, having previously worked as an addiction researcher at the University of Minnesota and The Scripps Research Institute in La Jolla, California, focusing on mechanisms of opioid addiction and chronic pain. She transitioned to public health where her work with the Baltimore Harm Reduction Coalition solidified her goal to promote reasonable and efficient drug policies. Carrie received her Ph.D. in pharmacology and neuroscience from the University of Minnesota and a master’s in public health from Johns Hopkins University.
Tan Walele is a European Registered Toxicologist with significant experience in risk assessment and risk management, in-vitro toxicity models and clinical research. At Fontem Ventures he is responsible for a team of scientists supporting non-tobacco, next generation products and heads up their stewardship function which includes liaising with external advisors, engagement and regulatory authorities and providing advice on and management of product testing strategies. In addition Tan is responsible for the compilation and provision of robust & substantive scientific information in support of products as required by regulations worldwide, to ensure their approval by government authorities. This includes the provision of dossiers through regulatory frameworks such as EUTPD, Medicinal Licensing and US FDA.
Tan's qualifications include: European Registered Toxicologist, ERT; Toxicology, MSc; Medical Biochemistry, BSc
Dr. Derek Yach, a global health expert and anti-smoking advocate for more than 30 years, is the president of the Foundation for a Smoke-Free World. Throughout his career, he has supported and led smoking cessation research and policy development and has been a strong proponent of harm-reduction policies, calling for a greater emphasis on harm reduction as early as 2005. He is also a passionate advocate of health promotion and disease prevention, and is advancing his career’s work at the Foundation for a Smoke-Free World. He has authored or co-authored more than 250 peer-reviewed articles on global health and has served on several advisory boards, including the World Economic Forum, Cornerstone Capital and the Wellcome Trust. From 2007 to 2016, he served on the program advisory committee of the Clinton Global Initiative. Dr. Yach is a native of South Africa and has an honorary DSc from Georgetown University, MBChB from the University of Cape Town, BSc (Hons Epi) from the University of Stellenbosch, and an MPH from the Johns Hopkins Bloomberg School of Public Health